How long to take Talazoparib

Talazoparib (Talazoparib) is a PARP (polymerase-ADP-ribose polymerase) inhibitor, used to treat metastatic breast cancer associated with BRCA gene mutations or metastatic castration-resistant prostate cancer with HRR gene mutations. The duration of treatment with this drug is usually determined by the doctor based on the patient's specific condition and response to treatment.

According to clinical prescribing guidelines for talazopanib, patients may continue treatment with talazopanib until disease progression or unacceptable toxicity occurs. In clinical studies, after oral administration of 1 mg of tazopanib once daily, the average AUC and maximum observed plasma concentration (Cmax) of tazopanib at steady state were 208 ngxhr/mL and 16.4 ng/mL, respectively, and reached steady state within 2-3 weeks of treatment. The range of Tmax is 1-2 hours. High-fat, high-calorie meals increased mean Cmax by 46% and median Tmax from 1 to 4 hours without affecting AUC. Usually, patients need to use talazopanib continuously for several months or longer under the guidance of a doctor. The specific taking time still needs to follow the doctor's prescription and recommendations.

The original drug of talazopanib has not yet been marketed in China, so it has not been included in medical insurance. The original drug specification of talazopanib listed overseas is 0.25mg*30 capsules, and the price per box may be around RMB 10,000 (the price may fluctuate due to exchange rate effects), which is relatively expensive. There are also cheaper generics of talazopanib overseas. For example, the price of a box of 1mg*30 pills produced by a Laos pharmaceutical factory may be more than 3,000 yuan (the price may fluctuate due to the exchange rate).